Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Income from Continuing Operations (2016 - 2025)

Sunshine Biopharma's Income from Continuing Operations history spans 13 years, with the latest figure at 5063102.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 16.86% year-over-year to 5063102.0; the TTM value through Dec 2025 reached 1228677.0, down 9.43%, while the annual FY2025 figure was 1228677.0, 9.43% down from the prior year.
  • Income from Continuing Operations reached 5063102.0 in Q4 2025 per SBFM's latest filing, up from 883820.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5063102.0 in Q4 2025 to a low of 23512315.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 2055084.1, with a median of 1217018.5 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: plummeted 6461.84% in 2021, then soared 446.59% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 667116.0 in 2021, then plummeted by 3624.47% to 23512315.0 in 2022, then surged by 94.68% to 1250024.0 in 2023, then skyrocketed by 446.59% to 4332476.0 in 2024, then rose by 16.86% to 5063102.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Income from Continuing Operations are 5063102.0 (Q4 2025), 883820.0 (Q3 2025), and 1770834.0 (Q2 2025).